Climb Bio’s CLYM116 Phase 1 supports every-12-week dosing in IgA nephropathy
Phase 1 for CLYM116 showed prolonged half-life, strong APRIL and IgA suppression, and a favorable safety profile, supporting Q12W dosing in IgA nephropathy. Phase 2/3 planned; key data expected in 2027.
CLYM116 demonstrated a prolonged half-life, strong APRIL and IgA suppression, and a favorable safety profile in Phase 1, supporting every-12-week dosing for IgA nephropathy.
Phase 2 and Phase 3 studies are planned, with key data expected in 2027.Original document: Climb Bio, Inc. [CLYM] Press relea…